Citadel Advisors
AQST icon

Citadel Advisors’s Aquestive Therapeutics AQST Stock Holding History

Citadel Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Sell
65,500
-60,600
-48% -$255K ﹤0.01% 11332
2026
Q1 		$523K Sell
126,100
-11,300
-8% -$45.9K ﹤0.01% 9190
2025
Q4 		$888K Sell
137,400
-66,900
-33% -$417K ﹤0.01% 7651
2025
Q3 		$1.14M Buy
204,300
+90,600
+80% +$392K ﹤0.01% 7241
2025
Q2 		$376K Sell
113,700
-22,900
-17% -$65.7K ﹤0.01% 9289
2025
Q1 		$396K Buy
136,600
+71,100
+109% +$215K ﹤0.01% 8991
2024
Q4 		$233K Buy
65,500
+5,400
+9% +$24.9K ﹤0.01% 10161
2024
Q3 		$299K Buy
60,100
+5,900
+11% +$23K ﹤0.01% 9338
2024
Q2 		$141K Sell
54,200
-53,700
-50% -$179K ﹤0.01% 10436
2024
Q1 		$460K Buy
107,900
+107,700
+53,850% +$359K ﹤0.01% 8580
2023
Q4 		$404 Sell
200
-1,200
-86% -$2.12K ﹤0.01% 14040
2023
Q3 		$2.14K Buy
1,400
+600
+75% +$1.03K ﹤0.01% 13759
2023
Q2 		$1.32K Buy
800
+500
+167% +$904 ﹤0.01% 13950
2023
Q1 		$342 Sell
300
-500
-63% -$433 ﹤0.01% 14516
2022
Q4 		$722 Buy
+800
New +$751 ﹤0.01% 14595
2022
Q2 		– Sell
-11,900
Closed -$31K – 12808
2022
Q1 		$31K Sell
11,900
-47,000
-80% -$137K ﹤0.01% 13083
2021
Q4 		$229K Buy
58,900
+26,700
+83% +$134K ﹤0.01% 11569
2021
Q3 		$140K Buy
32,200
+15,100
+88% +$59.2K ﹤0.01% 12454
2021
Q2 		$68K Sell
17,100
-43,100
-72% -$172K ﹤0.01% 13177
2021
Q1 		$313K Sell
60,200
-39,600
-40% -$211K ﹤0.01% 10748
2020
Q4 		$534K Buy
99,800
+51,700
+107% +$310K ﹤0.01% 8024
2020
Q3 		$234K Buy
48,100
+19,600
+69% +$128K ﹤0.01% 8567
2020
Q2 		$139K Buy
+28,500
New +$131K ﹤0.01% 8792

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Citadel Advisors's AQST Position: Q2 2026 in Review

Citadel Advisors reduced its Aquestive Therapeutics (AQST) stake by 20% in Q2 2026, selling an estimated $476K and leaving 452,197 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #6692.

Citadel Advisors first reported a position in AQST in Q3 2018 and has held it in 25 quarters since. The position peaked at $4.34M in Q3 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Citadel Advisors held 452,197 shares of Aquestive Therapeutics worth $1.88M as of Q2 2026.
  • Citadel Advisors sold 113,006 Aquestive Therapeutics shares in Q2 2026, an estimated $476K.
  • Aquestive Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6692 holding.
  • Citadel Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • Citadel Advisors's Aquestive Therapeutics position peaked at $4.34M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.